European panel publishes guidance on outpatient delivery of bispecifics
Using a modified Delphi approach, a panel of European experts generated consensus recommendations on safe and effective outpatient step-up-dosing of bispecific antibody (bsAb) therapies for patients with multiple myeloma (MM). The report, published in the European Journal of Haematology, also provides guidance on care transition from academic to community centers for bsAb recipients.
EHA 2026 will spotlight MM research in Plenary Abstracts Session
The 2026 Annual Congress of the European Hematology Association will include presentations on MM biological and translation research and clinical trials. Data from phase 3 MONUMENTAL-3 trial of the combination of talquetamab with daratumumab and pomalidomide in patients with RRMM who received ≥1 prior therapy will be featured in the Plenary Abstracts Session.
Bispecifics, ADC combinations, and CELMoDs among data featured at ASCO 2026
The 2026 American Society of Clinical Oncology Annual Meeting, held May 29–June 2, 2026, featured data from several MM clinical trials, including:
-
MajesTec-9, in which teclistamab reduced the risk of death by 40% (HR for overall survival comparison, 0.60), compared with pomalidomide-bortezomib-
dexamethasone or carfilzomib-dexamethasone (Kd) in patients with RRMM who had received 1 to 3 prior lines of therapy, including a CD38-targeted monoclonal antibody -
SUCCESSOR-2; the combination of the CELMoD mezigdomide with Kd showed a clinically meaningful progression-free benefit over Kd in patients with RRMM who had received ≥1 prior lines of therapy
-
DREAMM-9 in the frontline newly diagnosed myeloma (NDMM) setting; adding belantamab mafodotin (BEL) to triplet-based induction yielded high response rates in this phase 1 trial
-
Long-term results and subgroup/pooled analyses from the DREAMM-7 and DREAMM-8 studies of BEL combination regimens in RRMM
Rapidly manufactured BCMA CAR-T therapy shows preliminary efficacy
Durcabtagene autoleucel (durca-cel) is a BCMA-directed CAR-T therapy manufactured using a rapid platform, designed to accelerate CAR T-cell production and preserve T-cell stemness. In a phase 1 trial, durca-cel showed an overall response rate of 98%, with a minimal residual disease-negativity rate of 80%, in patients with RRMM. These findings were reported in Science Translational Medicine.
Review explores treatment-induced cardiotoxicity in MM
A review published in the Blood Cancer Journal highlights the impact of treatment-induced cardiotoxicity in MM clinical care. In addition to discussing epidemiology and mechanisms, the review contextualizes emerging evidence for risk stratification models and approaches for managing MM therapy-associated cardiotoxicities.
Low socioeconomic status adversely impacts HRQOL in patients with RRMM
Patients with RRMM who had low socioeconomic status had worse health-related quality-of-life (HRQOL) that those with higher socioeconomic status, according to a cross-sectional analysis conducted in the United Kingdom. The report, published in JCO Oncology Practice, also noted that financial toxicity related to the prolonged treatment for RRMM accounted for nearly half of the adverse impact on HRQOL.
